Header Logo

Connection

MARIA BOTTAZZI to Chagas Disease

Back to Details
This is a "connection" page, showing publications MARIA BOTTAZZI has written about Chagas Disease.
MARIA BOTTAZZI
Connection Strength
6.329
Chagas Disease
  1. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.433
  2. Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
    View in: PubMed
    Score: 0.377
  3. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
    View in: PubMed
    Score: 0.294
  4. Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl Trop Dis. 2012; 6(5):e1498.
    View in: PubMed
    Score: 0.289
  5. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis. 2009 Jul 07; 3(7):e470.
    View in: PubMed
    Score: 0.237
  6. Different responses involving Tfh cells delay parasite-specific antibody production in Trypanosoma cruzi acute experimental models. Front Immunol. 2025; 16:1487317.
    View in: PubMed
    Score: 0.177
  7. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
    View in: PubMed
    Score: 0.173
  8. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.164
  9. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
    View in: PubMed
    Score: 0.160
  10. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
    View in: PubMed
    Score: 0.159
  11. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.
    View in: PubMed
    Score: 0.156
  12. Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models. Microbiol Spectr. 2023 06 15; 11(3):e0019923.
    View in: PubMed
    Score: 0.154
  13. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.152
  14. Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022 11; 16(11):e0010376.
    View in: PubMed
    Score: 0.149
  15. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.146
  16. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.137
  17. Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. Front Cell Infect Microbiol. 2021; 11:708325.
    View in: PubMed
    Score: 0.137
  18. Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology. ACS Infect Dis. 2021 06 11; 7(6):1638-1649.
    View in: PubMed
    Score: 0.134
  19. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
    View in: PubMed
    Score: 0.132
  20. Mining the Metabolome for New and Innovative Chagas Disease Treatments. Trends Pharmacol Sci. 2021 01; 42(1):1-3.
    View in: PubMed
    Score: 0.130
  21. A new patient registry for Chagas disease. PLoS Negl Trop Dis. 2020 10; 14(10):e0008418.
    View in: PubMed
    Score: 0.129
  22. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 2020 10; 42(10):e12769.
    View in: PubMed
    Score: 0.127
  23. Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine. 2020 06 15; 38(29):4584-4591.
    View in: PubMed
    Score: 0.125
  24. Reproductive Outcomes in Rhesus Macaques (Macaca mulatta) with Naturally-acquired Trypanosoma cruzi Infection. Comp Med. 2020 04 01; 70(2):152-159.
    View in: PubMed
    Score: 0.124
  25. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.124
  26. Response to `letter to the editor: 'Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'?. Expert Rev Anti Infect Ther. 2019 09; 17(9):673-675.
    View in: PubMed
    Score: 0.119
  27. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.117
  28. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev Anti Infect Ther. 2019 03; 17(3):145-157.
    View in: PubMed
    Score: 0.115
  29. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.112
  30. Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Hum Vaccin Immunother. 2019; 15(1):210-219.
    View in: PubMed
    Score: 0.112
  31. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS Negl Trop Dis. 2018 01; 12(1):e0006240.
    View in: PubMed
    Score: 0.107
  32. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.106
  33. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.098
  34. The BENEFIT Trial: Where Do We Go from Here? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004343.
    View in: PubMed
    Score: 0.094
  35. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016 04 02; 12(4):976-87.
    View in: PubMed
    Score: 0.094
  36. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
    View in: PubMed
    Score: 0.090
  37. Limited antigenic variation in the Trypanosoma cruzi candidate vaccine antigen TSA-1. Parasite Immunol. 2014 Dec; 36(12):708-12.
    View in: PubMed
    Score: 0.086
  38. Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
    View in: PubMed
    Score: 0.085
  39. Trypanosoma cruzi screening in Texas blood donors, 2008-2012. Epidemiol Infect. 2016 Apr; 144(5):1010-3.
    View in: PubMed
    Score: 0.084
  40. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis. 2013; 7(10):e2300.
    View in: PubMed
    Score: 0.080
  41. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr; 13(4):342-8.
    View in: PubMed
    Score: 0.076
  42. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother. 2012 Sep; 8(9):1293-301.
    View in: PubMed
    Score: 0.073
  43. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008 Sep 24; 2(9):e300.
    View in: PubMed
    Score: 0.056
  44. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.034
  45. Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
    View in: PubMed
    Score: 0.026
  46. Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24. Am J Trop Med Hyg. 2016 Jan; 94(1):114-121.
    View in: PubMed
    Score: 0.023
  47. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.